Scleroderma

#Allergy #CHMP #FDA #Melanoma #Regulatory #Schizophrenia #Scleroderma

This week in drug discovery (26 Feb – 1 March) 

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative. The first therapy was approved for allergic reactions to food, a drug for scleroderma secured Fast Track Designation, and… Read More

#News

Fibrous dysplasia disease
#Certa Therapeutics #FDA #Scleroderma #Sclerosis

Scleroderma drug gets fast-tracked in the US 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma).  The Fast Track Designation was granted based on results of a Phase II study which indicated that treatment of scleroderma patients… Read More

#News #Regulatory